StockNews.AI
ASRT
StockNews.AI
13 days

Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors

1. Securities fraud claims against Spectrum Pharmaceuticals under investigation. 2. Allegations involve misleading statements about the Pinnacle Study results. 3. Spectrum's shares were delisted post-merger with Assertio Holdings (ASRT). 4. Investors can act as lead plaintiffs by September 2025. 5. Law firm Berger Montague represents affected investors in this case.

4m saved
Insight
Article

FAQ

Why Bearish?

The investigation and allegations against Spectrum could reflect negatively on ASRT due to their recent merger, reminiscent of historical cases where legal issues hampered stock performance.

How important is it?

The connection between Spectrum's issues and ASRT could influence investor sentiment and stock price, given the recent merger.

Why Short Term?

The immediate fallout from the legal issues will likely affect ASRT's stock performance in the coming weeks to months, similar to how past litigation impacts investor confidence.

Related Companies

SPPI
, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. Spectrum is a biopharmaceutical company focused on oncology treatments. The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients. Spectrum shares were delisted following the Company's merger with Assertio Holdings, Inc. (NASDAQ: ASRT). If you are a Spectrum investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865. About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015[email protected] Caitlin AdorniBerger Montague(267) 764-4865[email protected]  SOURCE Berger Montague WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News